AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

North County Parkinson's Support Group Fallbrook invites anyone interested to join their monthly support group meeting, every fourth Friday of the month. The next one is Friday, Feb. 28, 10 a.m. to ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

AbbVie is collaborating with a clinical-stage biotech company that's developing tumor-activated immuno-oncology therapies it hopes will not wreak havoc on the entire body. Under the terms, which ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...